MIT's Taris, which is developing a drug delivery system for bladder diseases, has been purchased by Johnson & Johnson.
Medical product group Johnson & Johnson acquired Taris Biomedical, a US-based drug delivery technology spinout of Massachusetts Institute of Technology, on Friday for an undisclosed amount.
Taris has created a silicon-based drug delivery system intended for use with therapeutics for bladder disease, including related cancers. The TAR-200 device enables medication to be continuously released into the bladder.
Bristol-Myers Squibb took part in the company’s $25m series B round, which was led by venture capital fund Yonghua Capital and…
